Ardelyx (ARDX) investor relations material

Commercial performance and growth outlook

• IBSRELA achieved 73% growth in 2025, with 2026 guidance of $410–$430 million, targeting a 50% growth rate and a path to $1 billion by 2029, requiring a 38% CAGR.

• XPHOZAH's Non-Medicare business grew 41% in 2025, with total dispenses up 9%, and 2026 guidance projects 5–10% growth.

• Investments in sales force expansion, field reimbursement, and distribution networks are key drivers for IBSRELA's continued growth.

• Primary care, gastroenterologists, and advanced practice providers collectively drive 50% of IBSRELA prescriptions, with ongoing efforts to deepen engagement.

• Top-line revenue is growing faster than expenses, with cash generation supporting future investments.

Pipeline development and clinical strategy

• The EXCEL Phase III trial for CIC is powered at 95% to detect a 14% difference, targeting enrollment completion by year-end and data readout in the second half of next year.

• CIC represents a patient population 2–3 times larger than IBS-C, with plans to expand sales reach into primary care as the indication grows.

• Messaging for CIC will focus on durable efficacy and a strong safety profile, leveraging prior IBS-C data.

• The next-generation NHE3 inhibitor program aims for greater solubility and potency, with IND submission planned by year-end and potential for broader indications.

• Opportunistic approach to future indications and partnerships, leveraging commercial and scientific strengths.

Financial management and investment priorities

• 2026 OpEx is guided to $520 million, with a steady spend profile and increased R&D allocation due to pipeline expansion.

• ROI is closely tracked for all programs, with field sales teams delivering the highest returns.

• Cash generation in recent quarters enables self-funded growth and strategic investments.

• Investments in commercial infrastructure are designed to support both current and future product launches.